The DMPK Knockout HeLa Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal cell population in which the DMPK gene has been disrupted to generate a loss-of-function model. This polyclonal pool originates from the widely used HeLa host cell line and provides a heterogeneous knockout background suitable for studying DMPK-dependent cellular processes without clonal selection artifacts. The CRISPR-mediated gene disruption enables researchers to interrogate DMPK function in a human epithelial context.
HeLa cells are an immortalized human cervical adenocarcinoma line positive for human papillomavirus type 18 (HPV18). They serve as a robust and well-characterized model for epithelial cell biology, cancer research, and signal transduction studies. The HeLa background offers ease of culture, reliable growth kinetics, and extensive historical data, making it a versatile platform for generating knockout derivatives. The epithelial origin of HeLa cells is particularly relevant for investigating cytoskeletal dynamics and cell migration, processes in which DMPK plays a critical role.
DMPK encodes a serine/threonine protein kinase that acts downstream of transcriptional regulators such as MyoD, MEF2, and serum response factor (SRF), and is responsive to mechanical stretch. This kinase phosphorylates key substrates including myosin phosphatase target subunit 1 (MYPT1), phospholamban (PLN), and CUGBP1 (CELF1), thereby modulating actin-myosin contractility and RNA metabolism. DMPK interacts with Rac1, HSPB2, CUGBP1, and actin filaments, integrating signals from Wnt/??-catenin pathway components including DVL, GSK-3??, and CTNNB1, as well as ROCK-mediated cytoskeletal reorganization. Through these interactions, DMPK coordinates calcium handling and cytoskeletal architecture.
In the context of HeLa epithelial cells, disruption of DMPK is expected to perturb actin filament organization, focal adhesion dynamics, and cell motility. Given HeLa’s origin from a cervical adenocarcinoma, this knockout model enables the dissection of DMPK??s contributions to cancer cell migration and invasion, as well as its potential non-muscle roles in epithelial homeostasis. Moreover, loss of DMPK function recapitulates aspects of myotonic dystrophy type 1 (DM1) pathology, including aberrant RNA processing, making this polyclonal population a valuable tool for mechanistic and therapeutic studies in DM1.
Researchers can employ these polyclonal knockout cells in a variety of functional assays. Western blotting confirms DMPK depletion, while immunofluorescence reveals actin cytoskeleton alterations and focal adhesion changes. Wound healing and transwell migration assays quantify cell motility, and phospho-proteomics can identify novel DMPK substrates or downstream phosphorylation events. Additionally, RT-qPCR of downstream target genes such as PLN or CUGBP1 validates signaling pathway engagement, and cell viability assays can assess sensitivity to candidate therapeutics. For further technical details, please contact Ascent Research.
